This course is not available at this time
Return to Course LibraryBibliography

Release Date:
December 21, 2019

Expiration Date:
January 1, 2022

FACULTY

Rufus J. Mark, MD
Medical Director, Radiation Oncology
Baylor Scott & White Charles A. Sammons Cancer Center
Assistant Clinical Professor, Radiation Oncology
Texas Tech University Health Sciences Center

 

 

 

 

5110-102A
EVOLUTION OF BREAST CONSERVATION THERAPY Archive
From whole breast x 6 weeks to partial breast x 1 week

A free one-hour lecture  recorded on November 12, 2019 with Rufus J. Mark, MD
for radiation oncologists, radiation therapists, breast surgeons, radiologists & nurses

Format: Archived Webinar
  0.75 AMA PRA Category 1
  0.75 ANCC Contact hour
  0.75 ARRT Category A
Tuition:  FREE

This course expires January 1, 2022

If you want credit, this course must be completed (i.e. view course content (PDF file), pass the posttest, AND print the certificate)

by no later than December 31, 2021 by 5:00PM

Please note, after this course has expired, no aspect of the course will be accessible, including the course link.

Course Overview
Whole breast irradiation (WBI) has been used for decades to ensure all cancers cells have been destroyed post-breast surgery, but WBI has several disadvantages, including the detrimental effects of radiation exposure to the surrounding organs and skin. Accelerated partial breast irradiation (APBI) precisely targets the desired volume of tissues, thereby reducing radiation exposure to non-target areas and with potentially improved cosmesis. [1]

Dr. Mark will discuss the history of breast conservation radiation therapy, the benefits and disadvantages of whole breast vs accelerated partial breast irradiation, as well as review available markers and devices for precision radiation guidance.

1. The American Society of Breast Surgeons. Performance and practice guidelines for breast-conserving surgery/partial mastectomy. https://www.breastsurgeons.org/docs/statements/Performance-and-Practice-Guidelines-for-Breast-Conserving-Surgery-Partial-Mastectomy.pdf.  Accessed August 20, 2019.

Educational Objectives
At the conclusion of this activity, participants should be better able to:

  • Compare and contrast whole breast irradiation (WBI) to accelerated partial breast irradiation (APBI), including radiation safety and patient satisfaction
  • Describe APBI options, including external beam radiation therapy, brachytherapy,  and intraoperative radiation therapy
  • Explain the advantages and disadvantages of devices currently used to ensure precision radiation therapy

Faculty
Rufus J. Mark, MD
Medical Director, Radiation Oncology
Baylor Scott & White Charles A. Sammons Cancer Center
Assistant Clinical Professor, Radiation Oncology
Texas Tech University Health Sciences Center
Waxahachie, TX

After graduating from Yale University, Dr. Mark received his medical degree from UCLA, where he completed a residency in Radiation Oncology. Dr. Mark has published or presented more than 250 papers or abstracts at peer-reviewed national and international meetings. His clinical research interests have included; the use of Gamma Knife Radiosurgery in the treatment of brain tumors; trigeminal neuralgia and Parkinson's disease; application of high-dose-rate (HDR) implants in the treatment of breast and prostate cancer; and most recently stereotactic body radiation therapy (SBRT) in the treatment of breast cancer. Dr. Mark is certified by the American Board of Radiation Oncology.

------------------------------------------

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and International Center for Postgraduate Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education to the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of
0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SA-CME: This activity meets the criteria for self-assessment toward the purpose of fulfilling requirements in the American Board of Radiology (ABR) Maintenance of Certification Program.

The European Accreditation Council for CME (EACCME®)
The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) for live event and e-learning materials.

For more information go to https://www.uems.eu/areas-of-expertise/cme-cpd/eaccme/mutual-recognition-with-the-united-states

Nurse Continuing Medical Education
The maximum number of hours awarded for this Continuing Nursing Education activity is
0.75 contact hours.

Radiologic Technologists
This program has been approved by the American Society of Radiologic Technologists (ASRT) for 0.75 hour of ARRT Category A continuing education credit.

----------------------------------

How to Enroll and Participate
There are no fees or prerequisites to participate in this program. Estimated time to complete this activity is one hour.
Click ENROLL NOW, CONTINUE, CONFIRM ORDER, and ACCESS COURSE NOW.

  • Click on the blue link. Complete the precourse questions and SUBMIT.
  • Click on the blue link again to view the recording.

How to Receive Credit

  • Log-in to your account at www.icpme.us
  • View the entire educational activity session. At the conclusion of the lecture, close the Vimeo window.
  • Return to the course in your account at www.icpme.us.
  • From the COURSE HOME page, click the button for POSTTEST and for EVALUATION.
  • A passing grade of at least 75% is required to receive credit. You may take the test up to three times.
  • Upon receipt of a passing grade, you will be able to print a certificate of credit from your account at www.icpme.us

Your certificate of credit will remain in your account at www.icpme.us as a permanent record of your participation.

Disclosure Information
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Rufus J. Mark, MD, has received consulting fees from Hologic, Inc.                       

ICPME and PIM planners and managers have no disclosures.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Questions?
For questions regarding this program, please contact ICPME:
Email: information@icpmed.com

               Jointly provided by
               
 

This activity is supported by an independent educational grant from Hologic, Inc.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.